Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 2Glioblastoma 2Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 119Temozolomide 109Carboplatin 52Filgrastim 46Vincristine 42Etoposide 39Cyclophosphamide 36Chemotherapy, Adjuvant 36Cisplatin 35Carmustine 32Irinotecan 27Peripheral Blood Stem Cell Transplantation 25Magnetic Resonance Spectroscopy 23Lomustine 22Thiotepa 21Methotrexate 19Granulocyte Colony-Stimulating Factor 18Procarbazine 16Bevacizumab 16Surgical Procedures, Operative 15O(6)-benzylguanine 14etoposide phosphate 13Topotecan 12Paclitaxel 12Ifosfamide 12Drug Therapy 12Thalidomide 11Radiation 11sargramostim 10Erlotinib Hydrochloride 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Central Nervous System Neoplasms × CT-322 × Clear all
NCT00562419 2010-10-27

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 2 Unknown
72 enrolled
CNS

Glioblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡